SCHEMBL3602181

SCHEMBL3602181

O=C(N[C@H]1CCNC1)c1cc2c(ccc3ccccc32)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 1/20 0.53
HSD17B10 Q99714 1/20 0.53
KDR P35968 1/20 0.52
JAK2 O60674 1/20 0.44
PARP1 P09874 1/20 0.44
SMYD3 Q9H7B4 3/20 0.44
MLLT1 Q03111 1/20 0.43
NPC1 O15118 1/20 0.41
NR1I2 O75469 1/20 0.41
HPGD P15428 1/20 0.41
AHR P35869 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GHSR Q92847 3/20 0.41
CHRNA7 P36544 1/20 0.40
HTR3A P46098 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598920 1.00 KDM4E (0.53) KDM4EALDH1A1LMNAHSD17B10KDR
SCHEMBL3598914 1.00 KDM4E (0.53) KDM4EALDH1A1LMNAHSD17B10KDR
Trifluoroacetic Acid SCHEMBL3601240 0.93 KDM4E (0.49) KDM4EALDH1A1LMNAHSD17B10KDR
Trifluoroacetic Acid SCHEMBL3602215 0.93 KDM4E (0.49) KDM4EALDH1A1LMNAHSD17B10KDR
SCHEMBL3603280 0.84 KDR (0.59) KDM4EALDH1A1LMNAHSD17B10KDR
SCHEMBL3603283 0.84 KDR (0.59) KDM4EALDH1A1LMNAHSD17B10KDR
SCHEMBL3605258 0.80 PARP1 (0.47) KDRPARP1SMYD3MLLT1
SCHEMBL3596393 0.80 PYGL (0.50) KDRJAK2PARP1SMYD3
SCHEMBL3615341 0.80 PARP1 (0.47) KDRPARP1SMYD3MLLT1
SCHEMBL3596390 0.80 PYGL (0.50) KDRJAK2PARP1SMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035862-A1 NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-02-11 US claimed
US-20100063080-A1 CXCR2 inhibitors PRESS NEIL JOHN 2010-03-11 US disclosed
US-20100035862-A1 NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2010-02-11 US disclosed
EP-2086947-A1 PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS Novartis AG (CH) 2009-08-12 EP disclosed
WO-2008061740-A1 PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035862-A1 NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF IDO2, IDO1, INMT KDM4E 963/4885ALDH1A1 513/4885LMNA 3287/4885
US-20100063080-A1 CXCR2 inhibitors CXCR2, CXCR1, CXCR3 KDM4E 4638/4885ALDH1A1 931/4885LMNA 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.